언어 선택

LGR5

LGR5 분자 정보

영어 이름	Leucine-rich repeat-containing G-protein coupled receptor 5	시판 약물 수	0
임상 약물 수	2	표적 별명	FEX，G Protein-Coupled Receptor 49，GRP49，HG38，G-protein coupled receptor HG38，GPR49，GPR67，G-protein coupled receptor 49，Leucine-rich repeat-containing G-protein coupled receptor 5，LGR5，Leucine Rich Repeat Containing G Protein-Coupled Receptor 5，G-Protein Coupled Receptor 67，Orphan G Protein-Coupled Receptor HG38
최고 연구 개발 단계	Phase 2 Clinical

영어 이름	Leucine-rich repeat-containing G-protein coupled receptor 5
표적 별명	FEX，G Protein-Coupled Receptor 49，GRP49，HG38，G-protein coupled receptor HG38，GPR49，GPR67，G-protein coupled receptor 49，Leucine-rich repeat-containing G-protein coupled receptor 5，LGR5，Leucine Rich Repeat Containing G Protein-Coupled Receptor 5，G-Protein Coupled Receptor 67，Orphan G Protein-Coupled Receptor HG38
시판 약물 수	0
임상 약물 수	2
최고 연구 개발 단계	Phase 2 Clinical

LGR5 제품 목록

속성
Protein (4)Cell (1)
제품 라이브러리
온라인 (5)
종
Human (4)Cynomolgus (1)
태그
His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)- (1)
마커
Unconjugated (3)Biotin-labeled (1)- (1)

제품 번호	종	발현 시스템	제품 설명
CHEK-ATP327	Human	HEK293	HEK293/Human LGR5 Stable Cell Line
LG5-H5253	Human	HEK293	Human LGR5 / GPR49 protein, Fc Tag
LG5-H52H3	Human	HEK293	Human LGR5 / GPR49 Protein, His Tag, low endotoxin
LG5-H82E4	Human	HEK293	Biotinylated Human LGR5 / GPR49 (22-561) Protein, His,Avitag™
LG5-C52H7	Cynomolgus	HEK293	Cynomolgus LGR5 / GPR49 protein, His Tag

총 수량5

LGR5분자 배경

LGR5 (also known as GPR49) is a seven-transmembrane protein of the class A Rhodopsin-like family of GPCRs. LGR5 and LGR4 bind the R-spondins with high affinity and mediate the potentiation of Wnt/β-catenin signaling by enhancing Wnt-induced LRP6 phosphorylation. The LGR5/RSPO complex could promote Wnt signalling via the neutralization of two transmembrane E3 ligases, RNF43 and ZNRF3.

LGR5분자 별명

LGR5, GPR49, GPR67, G-protein coupled receptor 49, G-protein coupled receptor 67, G-protein coupled receptor HG38, Leucine-rich repeat-containing G-protein coupled receptor 5

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Petosemtamab	MCLA-158	Phase 2 Clinical	Merus Nv	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms	상세
CNA-3103	CNA-3103	Phase 2 Clinical	Carina Biotech Pty Ltd	Colorectal Neoplasms	상세